Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma

NCT03068351 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03068351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03068351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
June 26, 2017
Completion date
August 1, 2019
Enrollment
24 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma